ReviewJournal of gastrointestinal cancer2025
Gallbladder Cancer and Peritoneal Metastasis: Is there any role of Cytoreductive Surgery (CRS) and/or Hyperthermic Intraperitoneal Chemotherapy (HIPEC)? A Narrative Review.
Review in Journal of gastrointestinal cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advanced poorly differentiated gallbladder carcinoma with focal poorly cohesive and signet-ring cell features.Clinical journal of gastroenterology · 2026Article
- Changing Perspectives in Managing Metastatic Gallbladder Cancer: Defining Oligometastatic Disease, Current Treatments, and Emerging Therapies.Journal of gastrointestinal cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGallbladder cancer (GBC) is the most common biliary tract cancer (BTC) worldwide-the majority of GBC patients present with locally advanced or metastatic disease. Peritoneum is one of the most common sites of metastasis in GBC and the most frequent site for recurrence after resection of both non-incidental and incidental GBC (iGBC). Ovarian, colorectal, and gastric cancers also commonly metastasise to the peritoneum, and the role of cytoreductive surgery (CRS) in the form of peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC) procedures is well-documented for the treatment of peritoneal metastasis (PM) or peritoneal dissemination or carcinomatosis in these malignancies. METHODS AND
resultsWe found ten reports (including five single case reports) of CRS + HIPEC in GBC + PM-both iGBC and non-iGBC. The number of patients ranged from as small as 3-5 to as many as 80. Major morbidity was uncommon; median survival ranged from 7 to 22 months, with 3-year survival around 20-30%. Three reports, including 1, 22, and 35 patients, showed the benefit of prophylactic HIPEC in selected patients with advanced GBC at high risk of developing PM during follow-up.
conclusionCRS and/or HIPEC may have a role in the management of PM in GBC.
Indexed as
Identifiers
40768006What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.